Related Experiment Videos

Cytotoxic brain oedema as a model in the examination of cerebroprotective substances

¹Institute of Pharmacology and Toxicology, Medical Academy Carl Gustav Carus, Dresden, FRG.

Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement

|January 1, 1991

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.

ESMO open·2025

[Device therapy after acute coronary syndrome].

Deutsche medizinische Wochenschrift (1946)·2014

Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells.

Osteoarthritis and cartilage·2010

Non-N-methyl-D-aspartate (NMDA) receptor antagonist 1,2,3, 4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulphonamide (NBQX) decreases functional disorders in cytotoxic brain oedema.

Archives of toxicology·2000

Nicardipine inhibits N-type calcium channels in dbcAMP-differentiated neuroblastoma x glioma hybrid cells (NG 108-15 cells).

Zhongguo yao li xue bao = Acta pharmacologica Sinica·1999

Valproate metabolites in the rat brain--regional distribution in various brain areas.

European journal of drug metabolism and pharmacokinetics·1999

See all related articles